Glenmark Pharmaceuticals Management
Management Kriterienprüfungen 1/4
Glenmark Pharmaceuticals' CEO ist Glenn Saldanha, ernannt in Jan 2001, hat eine Amtszeit von 23.33 Jahren. Die jährliche Gesamtvergütung beträgt ₹161.85M, bestehend aus 80.2% Gehalt und 19.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.35% der Aktien des Unternehmens, im Wert von ₹1.02B. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.5 Jahre bzw. 12.4 Jahre.
Wichtige Informationen
Glenn Saldanha
Geschäftsführender
₹161.9m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 80.2% |
| Amtszeit als Geschäftsführer | 23.6yrs |
| Eigentum des Geschäftsführers | 0.4% |
| Durchschnittliche Amtszeit des Managements | 1.8yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 12.6yrs |
Jüngste Management Updates
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Recent updates
Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Jan 18We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -₹19b |
| Dec 31 2023 | n/a | n/a | -₹8b |
| Sep 30 2023 | n/a | n/a | -₹1b |
| Jun 30 2023 | n/a | n/a | ₹3b |
| Mar 31 2023 | ₹162m | ₹130m | ₹3b |
| Dec 31 2022 | n/a | n/a | ₹9b |
| Sep 30 2022 | n/a | n/a | ₹8b |
| Jun 30 2022 | n/a | n/a | ₹8b |
| Mar 31 2022 | ₹158m | ₹130m | ₹9b |
| Dec 31 2021 | n/a | n/a | ₹10b |
| Sep 30 2021 | n/a | n/a | ₹10b |
| Jun 30 2021 | n/a | n/a | ₹10b |
| Mar 31 2021 | ₹139m | ₹110m | ₹10b |
| Dec 31 2020 | n/a | n/a | ₹10b |
| Sep 30 2020 | n/a | n/a | ₹9b |
| Jun 30 2020 | n/a | n/a | ₹9b |
| Mar 31 2020 | ₹122m | ₹91m | ₹8b |
| Dec 31 2019 | n/a | n/a | ₹7b |
| Sep 30 2019 | n/a | n/a | ₹6b |
| Jun 30 2019 | n/a | n/a | ₹8b |
| Mar 31 2019 | ₹157m | ₹131m | ₹9b |
| Dec 31 2018 | n/a | n/a | ₹9b |
| Sep 30 2018 | n/a | n/a | ₹9b |
| Jun 30 2018 | n/a | n/a | ₹7b |
| Mar 31 2018 | ₹162m | ₹134m | ₹8b |
Vergütung im Vergleich zum Markt: GlennDie Gesamtvergütung ($USD1.95M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Indian ($USD509.33K).
Entschädigung vs. Einkommen: GlennDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
Glenn Saldanha (54 yo)
23.6yrs
Amtszeit
₹161,850,000
Vergütung
Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Limited since 2000. Mr. Saldanha serves as Chairman at Ichnos Sciences Inc. Mr. Saldanha serv...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman | 23.6yrs | ₹161.85m | 0.35% ₹ 1.4b | |
| Global CFO & Executive Director | 6.8yrs | ₹102.47m | keine Daten | |
| Executive Director of Corporate Services & Executive Director | no data | ₹45.86m | 0.27% ₹ 1.1b | |
| Company Secretary & Compliance Officer | 7.5yrs | ₹5.71m | keine Daten | |
| President and Chief Human Resources Officer | 2.6yrs | keine Daten | keine Daten | |
| President & Head of Global Pharmaceutical Development | 1.9yrs | keine Daten | keine Daten | |
| President & Chief Quality Officer | less than a year | keine Daten | keine Daten | |
| President & Global Head of Formulation Operations | less than a year | keine Daten | keine Daten | |
| President & Business Head of India Formulations | less than a year | keine Daten | keine Daten | |
| President and Business Head of Europe & Emerging Markets | 1.6yrs | keine Daten | keine Daten | |
| President & Business Head of North America | less than a year | keine Daten | keine Daten | |
| Investor Relations Officer | no data | keine Daten | keine Daten |
1.8yrs
Durchschnittliche Betriebszugehörigkeit
55yo
Durchschnittliches Alter
Erfahrenes Management: GLENMARKDas Führungsteam des Unternehmens gilt nicht als erfahren (1.5 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman | 25.8yrs | ₹161.85m | 0.35% ₹ 1.4b | |
| Global CFO & Executive Director | 6.3yrs | ₹102.47m | keine Daten | |
| Executive Director of Corporate Services & Executive Director | 24.8yrs | ₹45.86m | 0.27% ₹ 1.1b | |
| Non Executive Director | 19yrs | ₹400.00k | 0.39% ₹ 1.6b | |
| Non-Executive Independent Director | 22.3yrs | ₹1.70m | 0.039% ₹ 154.8m | |
| Independent Non-Executive Director | 1.5yrs | ₹100.00k | keine Daten | |
| Independent Non-Executive Director | 4yrs | ₹900.00k | keine Daten | |
| Independent Non-Executive Director | 5.3yrs | ₹1.30m | keine Daten |
12.6yrs
Durchschnittliche Betriebszugehörigkeit
61yo
Durchschnittliches Alter
Erfahrener Vorstand: GLENMARKDie Vorstandsmitglieder sind sehr erfahren ( 12.4 ).